MX2016012483A - Inhibidores de quinasa a relacionada con tropomiosina (trka), composiciones y sus metodos. - Google Patents
Inhibidores de quinasa a relacionada con tropomiosina (trka), composiciones y sus metodos.Info
- Publication number
- MX2016012483A MX2016012483A MX2016012483A MX2016012483A MX2016012483A MX 2016012483 A MX2016012483 A MX 2016012483A MX 2016012483 A MX2016012483 A MX 2016012483A MX 2016012483 A MX2016012483 A MX 2016012483A MX 2016012483 A MX2016012483 A MX 2016012483A
- Authority
- MX
- Mexico
- Prior art keywords
- kinase inhibitors
- compositions
- methods
- disease
- trka kinase
- Prior art date
Links
- 101150111783 NTRK1 gene Proteins 0.000 title abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 108010025020 Nerve Growth Factor Proteins 0.000 abstract 2
- 102000015336 Nerve Growth Factor Human genes 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 229940053128 nerve growth factor Drugs 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000016192 Demyelinating disease Diseases 0.000 abstract 1
- 206010012305 Demyelination Diseases 0.000 abstract 1
- 206010067601 Dysmyelination Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 102000005937 Tropomyosin Human genes 0.000 abstract 1
- 108010030743 Tropomyosin Proteins 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 abstract 1
- -1 bicyclic heteroaryl benzamide compounds Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000007257 malfunction Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 239000003909 protein kinase inhibitor Substances 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2014/074143 WO2015143652A1 (en) | 2014-03-26 | 2014-03-26 | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| PCT/US2015/022004 WO2015148373A2 (en) | 2014-03-26 | 2015-03-23 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016012483A true MX2016012483A (es) | 2016-12-16 |
Family
ID=54193893
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016012483A MX2016012483A (es) | 2014-03-26 | 2015-03-23 | Inhibidores de quinasa a relacionada con tropomiosina (trka), composiciones y sus metodos. |
| MX2016012481A MX2016012481A (es) | 2014-03-26 | 2015-03-23 | Inhibidores de quinasa a relacionada con tropomiosina (trka), composiciones y sus metodos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016012481A MX2016012481A (es) | 2014-03-26 | 2015-03-23 | Inhibidores de quinasa a relacionada con tropomiosina (trka), composiciones y sus metodos. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9862707B2 (en:Method) |
| EP (2) | EP3122345B1 (en:Method) |
| JP (2) | JP2017512786A (en:Method) |
| KR (2) | KR20160131119A (en:Method) |
| CN (2) | CN106456582A (en:Method) |
| AU (2) | AU2015236438A1 (en:Method) |
| CA (2) | CA2942957A1 (en:Method) |
| MX (2) | MX2016012483A (en:Method) |
| RU (2) | RU2016141647A (en:Method) |
| WO (3) | WO2015143652A1 (en:Method) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105418615B (zh) * | 2015-12-09 | 2018-02-02 | 北京工业大学 | 苯甲酰胺衍生物及制备和应用 |
| WO2018236856A1 (en) * | 2017-06-19 | 2018-12-27 | University Of Maryland, Baltimore | Car activator agents for cyclophosphamide-based treatments of cancer |
| EP3692052A4 (en) | 2017-10-04 | 2021-03-17 | Dana Farber Cancer Institute, Inc. | INHIBITION BY SMALL MOLECULES OF THE TRANSCRIPTION FACTOR SALL4 AND ITS USES |
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| PL4053128T3 (pl) * | 2017-12-15 | 2025-01-27 | Biohaven Therapeutics Ltd. | Pochodne 5-(2-(2,5-difluorofenylo)pirolidyn-1-ylo)-3-(1h-pirazol-1-ilo)pirazolo[1,5-a]pirymidyny i pokrewne związki jako inhibitory kinaz trk do leczenia nowotworu |
| ES2965174T3 (es) | 2018-04-12 | 2024-04-11 | Bayer Ag | Derivados de N-(ciclopropilmetil)-5-(metilsulfonil)-n-{1-[1-(pirimidin-2-il)-1H-1,2,4-triazol-5-il]etil}heterociclilamida y compuestos similares como plaguicidas |
| KR102129114B1 (ko) * | 2018-07-26 | 2020-07-02 | 주식회사 온코파마텍 | TrkA 저해 활성을 갖는 화합물 및 이를 유효성분으로 함유하는 통증의 예방 또는 치료용 약학적 조성물 |
| US11969472B2 (en) | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
| EP3841098B1 (en) | 2018-08-22 | 2026-01-14 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (trk) degradation compounds and methods of use |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| CN111269233A (zh) * | 2018-12-05 | 2020-06-12 | 上海轶诺药业有限公司 | 一类咪唑并芳环类化合物的制备和应用 |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| CN117567338A (zh) | 2019-10-09 | 2024-02-20 | 拜耳公司 | 作为农药的新的杂芳基三唑化合物 |
| JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
| TW202134226A (zh) | 2019-11-18 | 2021-09-16 | 德商拜耳廠股份有限公司 | 作為殺蟲劑之新穎雜芳基-三唑化合物 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| KR20230010070A (ko) | 2020-02-26 | 2023-01-17 | 클루젠 (상하이), 인크. | 트로포미오신 수용체 키나제(trk) 분해 화합물 및 사용 방법 |
| WO2021197467A1 (zh) * | 2020-04-02 | 2021-10-07 | 上海华汇拓医药科技有限公司 | 多靶点的抗肿瘤化合物及其制备方法和应用 |
| AR122141A1 (es) * | 2020-05-28 | 2022-08-17 | Lilly Co Eli | Inhibidor de trka |
| CN113666862B (zh) * | 2021-08-18 | 2024-05-31 | 山东大学 | 一种通过镍催化不对称硝化反应制备手性3-硝基吲哚类化合物的方法 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB599834A (en) * | 1943-04-08 | 1948-03-22 | Francolor Sa | Improvements in or relating to the manufacture of azodyestuffs |
| AU680370B2 (en) * | 1994-06-21 | 1997-07-24 | Otsuka Pharmaceutical Factory, Inc. | Pyrazolo(1,5-a)pyrimidine derivative |
| IT1306704B1 (it) | 1999-05-26 | 2001-10-02 | Sirs Societa Italiana Per La R | Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. |
| DE19946322A1 (de) | 1999-09-28 | 2001-03-29 | Bayer Ag | Verfahren zur Konditionierung von Ionenaustauscherharzen |
| FR2807660A1 (fr) | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
| AU4878601A (en) * | 2000-04-20 | 2001-11-07 | Mitsubishi Corporation | Aromatic amide compounds |
| US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| US20050009876A1 (en) * | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
| KR100713137B1 (ko) * | 2001-06-28 | 2007-05-02 | 동화약품공업주식회사 | 신규의 2,4-디플루오로벤즈아미드 유도체 |
| ES2380054T3 (es) * | 2001-09-26 | 2012-05-08 | Pfizer Italia S.R.L. | Derivados de aminoindazol activos como inhibidores de quinasas, procedimientos para su preparación, y composiciones farmacéuticas que los contienen |
| US20030144518A1 (en) * | 2001-12-07 | 2003-07-31 | The Procter & Gamble Company | Process for preparing 3-acylamino-imidazo[1,2-a]pyridines |
| JP2003231687A (ja) * | 2002-02-04 | 2003-08-19 | Japan Tobacco Inc | ピラゾリル縮合環化合物及びその医薬用途 |
| WO2003068773A1 (en) * | 2002-02-12 | 2003-08-21 | Glaxo Group Limited | Pyrazolopyridine derivatives |
| US7098334B2 (en) * | 2002-03-25 | 2006-08-29 | Industrial Research Limited | 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases |
| EP1388341A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| PT2263692T (pt) | 2002-12-24 | 2018-11-28 | Rinat Neuroscience Corp | Anticorpos anti-ngf e métodos de utilização dos mesmos |
| RU2342365C2 (ru) | 2003-05-01 | 2008-12-27 | Бристол-Маерс Сквибб Компани | Арилзамещенные пиразоламиды в качестве ингибиторов киназ |
| TWI635096B (zh) | 2003-07-15 | 2018-09-11 | 安美基公司 | 作為選擇性神經生長因子（ｎｇｆ）通道抑制劑之人類抗-ｎｇｆ中和抗體 |
| WO2005030128A2 (en) | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Pyrazole modulators of metabotropic glutamate receptors |
| US20050143384A1 (en) | 2003-10-30 | 2005-06-30 | Eric Sartori | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 |
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| WO2005085227A1 (en) * | 2004-03-02 | 2005-09-15 | Smithkline Beecham Corporation | Inhibitors of akt activity |
| WO2005110994A2 (en) | 2004-04-30 | 2005-11-24 | Bayer Pharmaceuticals Corporation | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
| BRPI0608160A2 (pt) | 2005-02-16 | 2010-11-09 | Astrazeneca Ab | anticorpo isolado, célula hospedeira, método de inibir o crescimento de células psma+, e, uso de um anticorpo anti-psma defucosilado |
| EP1877057A1 (en) | 2005-04-27 | 2008-01-16 | AstraZeneca AB | Use of pyrazolyl-pyrimidine derivatives in the treatment of pain |
| WO2006123113A2 (en) | 2005-05-16 | 2006-11-23 | Astrazeneca Ab | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
| ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| ITRM20050332A1 (it) | 2005-06-24 | 2006-12-25 | Lay Line Genomics Spa | Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore. |
| EP1904452A2 (en) * | 2005-07-14 | 2008-04-02 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US20100216798A1 (en) | 2005-07-29 | 2010-08-26 | Astellas Pharma Inc | Fused heterocycles as lck inhibitors |
| DE102005042742A1 (de) | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| CA2623500A1 (en) | 2005-10-13 | 2007-04-19 | Devgen N.V. | Kinase inhibitors |
| EP1959944A1 (en) | 2005-12-15 | 2008-08-27 | Shionogi Co., Ltd. | A pharmaceutical composition comprising an amide derivative |
| CA2654898A1 (en) | 2006-07-07 | 2008-10-01 | Boehringer Ingelheim International Gmbh | New chemical compounds |
| US20100029619A1 (en) | 2006-08-04 | 2010-02-04 | Takeda Pharmaceutical Company Limted | Fused heterocyclic compound |
| BRPI0718266A2 (pt) | 2006-10-30 | 2014-01-07 | Novartis Ag | Compostos heterocíclicos como agentes anti-inflamatórios. |
| EP2155194B1 (en) | 2007-04-06 | 2015-01-21 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| GB0708188D0 (en) * | 2007-04-27 | 2007-06-06 | Merck Sharp & Dohme | Therapeutic compounds |
| MX2009013213A (es) * | 2007-06-08 | 2010-03-30 | Abbott Lab | Indazoles 5-sustituidos 5-heteroarilo como inhibidores de cinasa. |
| PE20090837A1 (es) | 2007-07-02 | 2009-07-24 | Boehringer Ingelheim Int | Nuevos compuestos quimicos |
| US20100240657A1 (en) | 2007-07-02 | 2010-09-23 | Boehringer Ingelheim International Gmbh | Chemical compounds |
| BRPI0814628B1 (pt) | 2007-07-20 | 2022-04-05 | Nerviano Medical Sciences S.R.L. | Derivados ativos de indazol substituídos como inibidores da quinase |
| PL2197849T3 (pl) | 2007-10-09 | 2013-05-31 | Merck Patent Gmbh | Pochodne n-(pirazolo-3-ylo)-benzamidowe jako aktywatory glukokinazowe |
| RS53350B (sr) * | 2008-09-22 | 2014-10-31 | Array Biopharma, Inc. | Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze |
| US8703962B2 (en) | 2008-10-24 | 2014-04-22 | Purdue Pharma L.P. | Monocyclic compounds and their use as TRPV1 ligands |
| KR101048448B1 (ko) * | 2008-11-21 | 2011-07-11 | 한국화학연구원 | 신규 피라졸로[4,3-ｂ]피리딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물 |
| CN106336400A (zh) | 2008-12-08 | 2017-01-18 | 萌蒂制药国际有限公司 | 酪氨酸激酶蛋白受体拮抗剂 |
| JP2012522013A (ja) | 2009-03-27 | 2012-09-20 | ザ ユーエービー リサーチ ファウンデーション | 調節ｉｒｅｓ媒介翻訳 |
| WO2011014775A1 (en) * | 2009-07-31 | 2011-02-03 | The Brigham And Women's Hospital, Inc. | Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses |
| RU2608611C2 (ru) * | 2009-11-05 | 2017-01-23 | Юниверсити Оф Нотр Дам Дю Лак | СОЕДИНЕНИЯ ИМИДАЗО[1,2-а] ПИРИДИНА, ИХ СИНТЕЗ И СПОСОБЫ ПРИМЕНЕНИЯ |
| PL2588475T3 (pl) | 2010-07-02 | 2015-10-30 | Gilead Sciences Inc | Inhibitory kinazy regulującej sygnał apoptozy |
| SG187209A1 (en) * | 2010-08-05 | 2013-03-28 | Amgen Inc | Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase |
| DK2611785T3 (da) | 2010-09-01 | 2014-08-25 | Bayer Ip Gmbh | N-(tetrazol-5yl)- og n- (triazol-5-yl) arylcarboxylsyreamider og deres anvendelse som herbicider |
| KR20130141500A (ko) * | 2010-09-29 | 2013-12-26 | 크리스탈지노믹스(주) | 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물 |
| US9079859B2 (en) | 2011-01-21 | 2015-07-14 | Auckland Uniservices Limited | Synthetic lethal targeting of glucose transport |
| EP2673270A1 (en) | 2011-02-09 | 2013-12-18 | Syngenta Participations AG | Insecticidal compounds |
| CN103649076B (zh) | 2011-05-13 | 2015-09-09 | 阵列生物制药公司 | 作为trka激酶抑制剂的吡咯烷基脲和吡咯烷基硫脲化合物 |
| CN102796103A (zh) | 2011-05-23 | 2012-11-28 | 南京英派药业有限公司 | 6-（芳基甲酰）咪唑并[1,2-a]嘧啶和6-（芳基甲酰）[1,2,4]三唑并[4,3-a]嘧啶作为Hedgehog抑制剂及其应用 |
| EP2714668B9 (en) | 2011-05-23 | 2017-06-14 | Merck Patent GmbH | Thiazole derivatives |
| US9102673B2 (en) * | 2011-07-12 | 2015-08-11 | Merck Sharp & Dohme Corp. | Substituted pyrrolo[3,2-c]pyridines as TrkA kinase inhibitors |
| WO2013074518A1 (en) * | 2011-11-14 | 2013-05-23 | Tesaro, Inc. | Modulating certain tyrosine kinases |
| EA025352B1 (ru) * | 2011-12-12 | 2016-12-30 | Др. Редди'С Лабораториз Лтд. | ЗАМЕЩЕННЫЕ СОЕДИНЕНИЯ ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ТРОПОМИОЗИН-РЕЦЕПТОРНОЙ КИНАЗЫ (Trk) |
| EP2689778A1 (en) * | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindoles or diazaindoles for treating pain |
| EP2689779A1 (en) * | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk |
| TWI652014B (zh) * | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | 雜環取代之雙環唑殺蟲劑 |
-
2014
- 2014-03-26 WO PCT/CN2014/074143 patent/WO2015143652A1/en not_active Ceased
-
2015
- 2015-03-23 US US15/128,793 patent/US9862707B2/en active Active
- 2015-03-23 RU RU2016141647A patent/RU2016141647A/ru not_active Application Discontinuation
- 2015-03-23 AU AU2015236438A patent/AU2015236438A1/en not_active Abandoned
- 2015-03-23 JP JP2016558347A patent/JP2017512786A/ja active Pending
- 2015-03-23 EP EP15769224.5A patent/EP3122345B1/en active Active
- 2015-03-23 US US15/129,206 patent/US9862716B2/en active Active
- 2015-03-23 KR KR1020167029497A patent/KR20160131119A/ko not_active Withdrawn
- 2015-03-23 MX MX2016012483A patent/MX2016012483A/es unknown
- 2015-03-23 KR KR1020167029495A patent/KR20160132114A/ko not_active Withdrawn
- 2015-03-23 CA CA2942957A patent/CA2942957A1/en not_active Abandoned
- 2015-03-23 CN CN201580027484.1A patent/CN106456582A/zh active Pending
- 2015-03-23 JP JP2016558339A patent/JP2017508766A/ja active Pending
- 2015-03-23 AU AU2015236363A patent/AU2015236363A1/en not_active Abandoned
- 2015-03-23 WO PCT/US2015/022004 patent/WO2015148373A2/en not_active Ceased
- 2015-03-23 MX MX2016012481A patent/MX2016012481A/es unknown
- 2015-03-23 WO PCT/US2015/021952 patent/WO2015148354A2/en not_active Ceased
- 2015-03-23 CN CN201580027483.7A patent/CN106456581A/zh active Pending
- 2015-03-23 CA CA2942817A patent/CA2942817A1/en not_active Abandoned
- 2015-03-23 EP EP15769051.2A patent/EP3122344B1/en active Active
- 2015-03-23 RU RU2016141645A patent/RU2016141645A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160131119A (ko) | 2016-11-15 |
| WO2015148354A3 (en) | 2015-12-03 |
| CN106456581A (zh) | 2017-02-22 |
| EP3122345A4 (en) | 2017-10-04 |
| WO2015148373A3 (en) | 2015-11-26 |
| RU2016141645A (ru) | 2018-04-27 |
| JP2017508766A (ja) | 2017-03-30 |
| RU2016141647A3 (en:Method) | 2018-06-26 |
| JP2017512786A (ja) | 2017-05-25 |
| CN106456582A (zh) | 2017-02-22 |
| RU2016141645A3 (en:Method) | 2018-10-26 |
| CA2942957A1 (en) | 2015-10-01 |
| US9862716B2 (en) | 2018-01-09 |
| RU2016141647A (ru) | 2018-04-27 |
| US20170107204A1 (en) | 2017-04-20 |
| WO2015143652A8 (en) | 2015-12-10 |
| WO2015148373A2 (en) | 2015-10-01 |
| MX2016012481A (es) | 2016-12-16 |
| KR20160132114A (ko) | 2016-11-16 |
| EP3122344A2 (en) | 2017-02-01 |
| EP3122345A2 (en) | 2017-02-01 |
| AU2015236363A1 (en) | 2016-09-01 |
| WO2015148354A2 (en) | 2015-10-01 |
| US9862707B2 (en) | 2018-01-09 |
| AU2015236438A1 (en) | 2016-09-01 |
| US20170114056A1 (en) | 2017-04-27 |
| CA2942817A1 (en) | 2015-10-01 |
| EP3122344B1 (en) | 2022-04-27 |
| WO2015143652A1 (en) | 2015-10-01 |
| EP3122344A4 (en) | 2017-09-06 |
| EP3122345B1 (en) | 2020-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016012481A (es) | Inhibidores de quinasa a relacionada con tropomiosina (trka), composiciones y sus metodos. | |
| MX2016012480A (es) | Inhibidores de quinasa a relacionada con tropomiosina (trka), composiciones y sus metodos. | |
| WO2015042085A3 (en) | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | |
| WO2015148350A3 (en) | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | |
| MX2020011774A (es) | Compuestos de naftiridina como inhibidores de quinasa jak. | |
| WO2016164286A3 (en) | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | |
| PH12017501817A1 (en) | Heterocyclic compounds as lsd1 inhibitors | |
| MX387394B (es) | Compuestos heterociclicos como inhibidores de la cinasa ret. | |
| SG10201908028SA (en) | Cyclopropylamines as lsd1 inhibitors | |
| MX2017009571A (es) | Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer. | |
| MX2017004129A (es) | Derivado de acido 4-(4-(4-fenilureido-naftalen-1-il)oxi-piridin-2- il)amino-benzoico como inhibidor de quinasa p38. | |
| MX2020004506A (es) | Derivados del bipirazol como inhibidores de janus cinasa (jak). | |
| SV2017005434A (es) | 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| GEAP202115340A (en) | Pyrimidine compound as jak kinase inhibitor | |
| MX2020006365A (es) | Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14). | |
| CO2017005588A2 (es) | 2-amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| PH12017500401A1 (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
| BR112017008039A2 (pt) | derivados de pirazol como inibidores de nik | |
| TW201613896A (en) | Novel 2,5-substituted pyrimidines | |
| MX2017000524A (es) | Compuestos novedosos de pirimidina sustituida. | |
| EA033238B1 (ru) | Новые производные тиенопиримидина в качестве ингибиторов nik | |
| MX366840B (es) | Pirimidinas novedosas 2,5-sustituidas como inhibidores de pde. | |
| MX2016010268A (es) | Pirimidinimidazolaminas como modulares de actividad de cinasa. |